FabF-FadM Cooperate to Recycle Fatty Acids and Rescue ΔplsX Lethality in Staphylococcus aureus

This study reveals that *Staphylococcus aureus* bypasses the lethality of a *plsX* deletion through cooperative mutations in *fabF* and *fadM* that facilitate the premature release and recycling of fatty acids, thereby enabling phospholipid synthesis while concurrently increasing sensitivity to $\beta$-lactam antibiotics.

The Gist

The Big Picture: A Broken Assembly Line

Imagine a bacterial cell, specifically Staphylococcus aureus (the "Staph" bacteria), as a busy factory. One of the most critical jobs in this factory is building the walls (the cell membrane). To build these walls, the factory needs bricks (fatty acids).

Normally, the factory has two ways to get these bricks:

1. Make them: A dedicated assembly line (called FASII) builds the bricks from scratch.
2. Buy them: The factory can buy pre-made bricks from the outside world (exogenous fatty acids).

There is a crucial manager named PlsX. PlsX's job is to take the bricks coming off the assembly line and hand them over to the wall-building crew. Without PlsX, the wall-building crew stops working, and the factory collapses. In fact, scientists thought PlsX was so important that if you removed it, the bacteria would die immediately.

The Mystery: The "Ghost" Survival

The researchers deleted the plsX gene (fired the manager). As expected, the bacteria couldn't grow on a standard diet. But then, something weird happened. After a while, a few "rogue" bacteria started growing again, even without the manager and without buying bricks from outside.

How? They found a way to steal the bricks from the assembly line before they were supposed to be used.

The Two "Hackers": FabF and FadM

The researchers discovered that these rogue bacteria had mutated (changed their code) in one of two specific places to make this theft possible:

1. The Sabotaged Machine (FabF):

   • The Analogy: Imagine the assembly line has a machine called FabF that stretches the bricks to make them longer. In the rogue bacteria, this machine got a glitch (a mutation). Instead of stretching the brick perfectly, it started dropping the brick halfway through the process.
   • The Result: The "dropped" bricks fell off the line, became free-floating, and were grabbed by the wall-building crew. The wall got built, but the bricks were shorter than usual.

2. The Overworked Catcher (FadM):

   • The Analogy: There is another protein called FadM. Think of it as a security guard or a catcher standing near the machine. Its normal job is to catch specific waste products. But in the rogue bacteria, the catcher got a mutation that made it better at grabbing the bricks directly from the machine before they could be stretched.
   • The Result: The catcher snatched the bricks, freeing them up for the wall-building crew.

The Twist: The researchers found that these two hackers must work together. If you have the broken machine (FabF mutation) but the catcher is completely missing (no FadM), the bacteria still die. The broken machine needs the catcher to help it drop the bricks. It's a team effort to bypass the manager (PlsX).

The Side Effects: Short Walls and Weak Defenses

While these hacks saved the bacteria from dying, they created two major problems:

1. Shorter Bricks: Because the bricks were dropped early, the new walls were made of shorter, weaker bricks.
2. The Antibiotic Weakness: This is the most exciting part for doctors. The bacteria with these hacked walls became much more sensitive to common antibiotics (like amoxicillin).
   • The Analogy: Think of the bacteria's armor (its resistance to antibiotics) as a shield made of long, interlocking bricks. Because the hacked bacteria used short, misshapen bricks, their shield had gaps. The antibiotics could slip right through the cracks and kill the bacteria much easier than before.

Why This Matters

This study is like finding a secret backdoor in a fortress.

• The Discovery: We learned that bacteria have a hidden "emergency exit" (the FabF-FadM relay) that lets them survive even when their main supply chain is cut.
• The Opportunity: While this escape route helps the bacteria survive the loss of PlsX, it actually makes them weaker against standard antibiotics.
• The Future: This suggests that if we can force bacteria to use this "leaky" pathway (perhaps by tweaking their metabolism), we might be able to make even the toughest "superbugs" (MRSA) vulnerable to the antibiotics we already have.

In short: The bacteria found a way to steal their own parts to survive a crisis, but in doing so, they built a weaker house that is easier for our medicine to knock down.

Technical Summary

1. Problem Statement

In Staphylococcus aureus, the enzyme PlsX (an acyltransferase) is traditionally considered essential for initiating phospholipid synthesis. PlsX converts the end-product of the Fatty Acid Synthesis II (FASII) pathway, acyl-ACP, into acyl-phosphate, which is then used by PlsY and PlsC to build phospholipids.

• The Constraint: Without PlsX, S. aureus cannot initiate phospholipid synthesis unless exogenous fatty acids (FAs) are available in the environment to be phosphorylated by the FA kinase (Fak) and bypass the PlsX step.
• The Gap: While PlsX is essential in standard laboratory conditions, the mechanisms by which S. aureus might survive a plsX deletion without external FA supplementation were unknown. Understanding this is crucial for elucidating membrane homeostasis and potential antibiotic targets, particularly given the link between membrane composition and $\beta$-lactam resistance in MRSA.

2. Methodology

The researchers employed a combination of genetic engineering, whole-genome sequencing, biochemical assays, and phenotypic analysis:

• Strain Construction: Created in-frame $\Delta$plsX mutants in two genetic backgrounds: RN-R (a repaired RN4220 derivative) and JE2 (USA300 MRSA).
• Suppressor Isolation: Plated $\Delta$plsX mutants on FA-free BHI medium to isolate spontaneous suppressors that regained the ability to grow.
• Genomic Analysis: Used Whole Genome Sequencing (WGS) and PCR to identify the specific mutations responsible for the suppressor phenotype.
• Genetic Interrogation:
  • Created transposon insertion mutants ($\Delta$fadM::Tn) to test gene essentiality.
  • Used phage transduction to introduce mutations into different genetic backgrounds.
  • Tested the effect of the FabF inhibitor platensimycin to mimic the suppressor phenotype chemically.
• Biochemical Characterization:
  • Fatty Acid Profiling: Gas Chromatography (GC) to analyze membrane fatty acid chain lengths.
  • Acyl-ACP Detection: Non-denaturing gel electrophoresis and Western blotting with anti-ACP antibodies to visualize FASII intermediates.
  • Antibiotic Sensitivity: E-tests to determine Minimum Inhibitory Concentrations (MICs) for amoxicillin.
  • FASII Bypass Assays: Growth tests in the presence of the FASII inhibitor AFN-1252 to determine if the suppressors could utilize exogenous FAs to bypass FASII.

3. Key Contributions

The study identifies a novel, cooperative mechanism between two proteins, FabF and FadM, that allows S. aureus to bypass the essentiality of PlsX by recycling internal fatty acids.

• Discovery of Suppressors: Identified that point mutations in either fabF (encoding 3-oxoacyl-ACP synthase II) or fadM (encoding a bifunctional acyl-CoA thioesterase/ACP binding protein) can rescue $\Delta$plsX lethality.
• Mechanism of Action: Proposed that these mutations facilitate the premature release of fatty acids from FASII intermediates (acyl-ACP), allowing them to be phosphorylated by Fak and enter the phospholipid synthesis pathway.
• Epistasis/Cooperation: Demonstrated that FabF and FadM function in the same pathway; specifically, FabF suppressors require the presence of functional FadM to rescue growth.
• Clinical Implication: Revealed that while these mutations rescue growth, they sensitize MRSA strains to $\beta$-lactam antibiotics (amoxicillin).

4. Key Results

A. Identification of Suppressor Mutations

• fabF Mutants: Isolated suppressors carried a specific point mutation FabF$^{A119E}$ (Alanine to Glutamic acid). A second mutation (FabF$^{D266A}$) was found but was unstable.
• fadM Mutants: Isolated suppressors carried mutations in the fadM gene (SAUSA300_1247). Specific variants included FadM$^{I38T}$, FadM$^{Y90F}$, and FadM$^{Y133F}$.
• Location: The FadM mutations map to the predicted fatty acid binding cavity/tunnel, suggesting they alter substrate binding or enzyme activity.

B. Mechanism of Rescue

• Premature FA Release: Both suppressor types resulted in membrane phospholipids with shortened fatty acid chains (reduction in C18:0 and C20:0). This suggests that the mutations cause the FASII machinery to release fatty acids prematurely before full elongation.
• Role of FadM:
  • A complete fadM null mutant ($\Delta$fadM::Tn) failed to suppress the $\Delta$plsX phenotype.
  • Introducing the $\Delta$fadM::Tn allele into a fabF suppressor strain abolished the growth rescue.
  • Conclusion: FadM is required for the FabF suppressor phenotype. The authors propose that FadM acts as an "ACP binding partner" that facilitates the release of the acyl chain from the FabF intermediate.
• Inhibition Mimicry: Treatment of $\Delta$plsX strains with sub-inhibitory concentrations of platensimycin (a FabF inhibitor) also rescued growth, supporting the hypothesis that reduced FabF processivity leads to FA release.

C. Metabolic Pathway Analysis

• FASII Dependency: The suppressors could not bypass FASII inhibition (AFN-1252) even in the presence of exogenous FAs. This proves that the suppressors do not compensate for the reverse PlsX reaction (converting acyl-PO4 back to acyl-ACP) and that active FASII is still required to generate the initial acyl-ACP.
• Model: The proposed model is:
  1. FabF (mutated or inhibited) stalls, releasing acyl-ACP.
  2. FadM (mutated in its binding cavity) binds the ACP, preventing re-elongation and promoting FA release.
  3. Free FAs are phosphorylated by Fak and used by PlsY/PlsC to synthesize phospholipids, bypassing the need for PlsX.

D. Antibiotic Sensitivity

• $\beta$-Lactam Sensitivity: Both fabF and fadM suppressor strains showed significantly increased sensitivity to amoxicillin compared to the parental MRSA strain.
• Hypothesis: The altered membrane composition (shorter fatty acids) likely destabilizes the oligomerization of PBP2a (the resistance protein), rendering the bacteria susceptible to $\beta$-lactams.

5. Significance

• Metabolic Flexibility: The study reveals a previously unknown "overflow valve" mechanism in S. aureus where FadM and FabF cooperate to regulate the flux between FASII and phospholipid synthesis. Under stress or mutation, this system allows the bacteria to recycle internal fatty acids to survive the loss of PlsX.
• Therapeutic Potential: The finding that bypassing PlsX essentiality via FabF/FadM mutations sensitizes MRSA to $\beta$-lactams suggests a potential synergistic therapeutic strategy. Targeting the FabF-FadM interaction or membrane homeostasis could resensitize resistant MRSA strains to standard $\beta$-lactam antibiotics.
• Drug Target Validation: It highlights FadM as a critical modulator of membrane lipid homeostasis and a potential target for novel antimicrobials, particularly in combination with existing cell wall synthesis inhibitors.

In summary, the paper demonstrates that S. aureus can overcome the essentiality of PlsX through a cooperative mechanism involving FabF and FadM that releases internal fatty acids for membrane synthesis, a process that inadvertently compromises the bacteria's resistance to $\beta$-lactam antibiotics.